Cargando…

Adrenal SGLT1 or SGLT2 as predictors of atherosclerosis under chronic stress based on a computer algorithm

BACKGROUND: Chronic stress promotes the development of atherosclerosis, causing disruptions in the body’s hormone levels and changes in the structural function of organs. OBJECTIVE: The purpose of this study was to investigate the pathological changes in the adrenal gland in a model of atheroscleros...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Jianyi, Meng, Lingbing, Wu, Dishan, Xu, Hongxuan, Hu, Xing, Hu, Gaifeng, Chen, Yuhui, Xu, Jiapei, Gong, Tao, Liu, Deping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	PeerJ Inc. 2023
Materias:	Biochemistry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474830/ https://www.ncbi.nlm.nih.gov/pubmed/37663275 http://dx.doi.org/10.7717/peerj.15647

Ejemplares similares

Self-reported prevalence and potential factors influencing cardio-cerebral vascular disease among the Chinese elderly: A national cross-sectional study
por: Meng, Lingbing, et al.
Publicado: (2022)

Editorial: Clinical prospective of SGLT2 inhibitors in atherosclerosis
por: Capuano, Annalisa, et al.
Publicado: (2022)

Chronic unpredictable mild stress promotes atherosclerosis via adipose tissue dysfunction in ApoE(-/-) mice
por: Mao, Min, et al.
Publicado: (2023)

The Role of SGLT2 Inhibitors in Atherosclerosis: A Narrative Mini-Review
por: Pahud de Mortanges, Aurélie, et al.
Publicado: (2021)

SGLT2 and cancer
por: Wright, Ernest M.
Publicado: (2020)

Novel natural and synthetic inhibitors of solute carriers SGLT1 and SGLT2
por: Oranje, Paul, et al.
Publicado: (2019)

Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor: In the heart of the problem
por: Vallianou, Natalia G., et al.
Publicado: (2021)

A Fluorescent Glucose Transport Assay for Screening SGLT2 Inhibitors in Endogenous SGLT2-Expressing HK-2 Cells
por: Lu, Yan-Ting, et al.
Publicado: (2018)

SGLT1 and SGLT1 Inhibitors: A Role to Be Assessed in the Current Clinical Practice
por: Spatola, Leonardo, et al.
Publicado: (2017)

Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2
por: Ghezzi, Chiara, et al.
Publicado: (2018)

Effects of SGLT2 Inhibitors beyond Glycemic Control—Focus on Myocardial SGLT1
por: Sayour, Alex Ali, et al.
Publicado: (2021)

Mechanistic evaluation of the inhibitory effect of four SGLT-2 inhibitors on SGLT 1 and SGLT 2 using physiologically based pharmacokinetic (PBPK) modeling approaches
por: Zhang, Yu, et al.
Publicado: (2023)

Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF
por: Bode, David, et al.
Publicado: (2021)

Effects and mechanisms of SGLT2 inhibitors on the NLRP3 inflammasome, with a focus on atherosclerosis
por: Yang, Liu, et al.
Publicado: (2022)

Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
por: Wicik, Zofia, et al.
Publicado: (2022)

Does SGLT1 inhibition add to the benefits of SGLT2 inhibition in the prevention and treatment of heart failure?
por: Pitt, Bertram, et al.
Publicado: (2022)

Mouse Models with SGLT2 Mutations: Toward Understanding the Role of SGLT2 beyond Glucose Reabsorption
por: Unno, Keiko, et al.
Publicado: (2023)

The anti-inflammatory effects of SGLT inhibitors
por: García-Ropero, Álvaro, et al.
Publicado: (2019)

SGLT2 Inhibitors and Their Antiarrhythmic Properties
por: Kolesnik, Ewald, et al.
Publicado: (2022)

Neuroprotective Effect of SGLT2 Inhibitors
por: Pawlos, Agnieszka, et al.
Publicado: (2021)

Structural mechanism of SGLT1 inhibitors
por: Niu, Yange, et al.
Publicado: (2022)

Benefits of SGLT2 inhibitors in arrhythmias
por: Gao, Jinghan, et al.
Publicado: (2022)

Thioglycosides as inhibitors of hSGLT1 and hSGLT2: Potential therapeutic agents for the control of hyperglycemia in diabetes
por: Castaneda, Francisco, et al.
Publicado: (2007)

LP-925219 maximizes urinary glucose excretion in mice by inhibiting both renal SGLT1 and SGLT2
por: Powell, David R, et al.
Publicado: (2015)

Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes
por: Sands, Arthur T., et al.
Publicado: (2015)

Targeting high glucose-induced epigenetic modifications at cardiac level: the role of SGLT2 and SGLT2 inhibitors
por: Scisciola, Lucia, et al.
Publicado: (2023)

The Role of SGLT2 Inhibitor on the Treatment of Diabetic Retinopathy
por: Sha, Wenjun, et al.
Publicado: (2020)

SGLT2 Inhibitors in Diabetic Patients With Cardiovascular Disease or at High Cardiovascular Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Zhao, Zinan, et al.
Publicado: (2022)

Use of systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in renal glucose reabsorption in humans
por: Lu, Yasong, et al.
Publicado: (2014)

Ghrelin Facilitates GLUT2-, SGLT1- and SGLT2-mediated Intestinal Glucose Transport in Goldfish (Carassius auratus)
por: Blanco, Ayelén Melisa, et al.
Publicado: (2017)

Electrocardiographic changes associated with SGLT2 inhibitors and non-SGLT2 inhibitors: A multi-center retrospective study
por: Wu, Victor Chien-Chia, et al.
Publicado: (2022)

Hereditary renal glycosuria, diabetes and responses to SGLT2 inhibitor
por: Ren, Qian, et al.
Publicado: (2022)

The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE(−/−) Mice
por: Leng, Weiling, et al.
Publicado: (2016)

Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice
por: Pennig, Jan, et al.
Publicado: (2019)

Clinical efficacy of SGLT2 inhibitors with different SGLT1/SGLT2 selectivity in cardiovascular outcomes among patients with and without heart failure: A systematic review and meta-analysis of randomized trials
por: Lee, Mei-Chuan, et al.
Publicado: (2022)

Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics
por: Liu, Zhenghong, et al.
Publicado: (2021)

Effects of SGLT2 Inhibitors on Atherosclerosis: Lessons from Cardiovascular Clinical Outcomes in Type 2 Diabetic Patients and Basic Researches
por: Xu, Jing, et al.
Publicado: (2021)

SGLT-2 inhibitors and their potential in the treatment of diabetes
por: Rosenwasser, Rebecca F, et al.
Publicado: (2013)

Nephroprotection by SGLT2 Inhibition: Back to the Future?
por: De Nicola, Luca, et al.
Publicado: (2020)

Recommendations on the Proper Use of SGLT2 Inhibitors
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5oj75iqphmf9kdq2dfqg1ntfi3